Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
Sabrina Chiara CecereLucia MusacchioMichele BartolettiVanda SalutariLaura ArenareDomenica LorussoGraziana RonzinoRossella LauriaGennaro CormioEmanuele NaglieriPaolo ScolloClaudia MarchettiFrancesco RaspagliesiStefano GreggiSaverio CinieriAlice BergaminiMichele OrdituraGiorgio ValabregaGiovanni ScambiaFabio MartinelliElisabetta De MatteisCinzia CardalesiVera LoizziGiorgia PerniolaClaudia CarellaGiuseppa ScandurraGaia GiannoneSandro PignataPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)
Cytoreductive surgery performed before platinum therapy and olaparib maintenance was associated with longer progression-free survival and overall survival in BRCA-mutated platinum-sensitive relapsed ovarian cancer patients. In accordance with our preliminary results, the response rate to chemotherapy given after progression during olaparib was associated with platinum-free interval.
Keyphrases
- free survival
- minimally invasive
- coronary artery bypass
- locally advanced
- acute lymphoblastic leukemia
- acute myeloid leukemia
- surgical site infection
- diffuse large b cell lymphoma
- multiple myeloma
- stem cells
- squamous cell carcinoma
- wild type
- breast cancer risk
- rectal cancer
- radiation therapy
- cell therapy
- chemotherapy induced
- mesenchymal stem cells
- atrial fibrillation
- bone marrow